AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-45. (Canceled).

46. (Previously Presented) A method for treating a wound and/or improving wound healing comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a peptide derived from amino acid 12 to amino acid 40 of human lactoferrin to a patient in need thereof, wherein:

said peptide inhibits a pro-inflammatory cytokine;

said peptide comprises ^{20}Cys-Phe-X_1-X_2-X_3-X_4-X_5-X_6-X_7-Lys-Val-Arg^{31} (SEQ ID NO: 99), wherein X_1 is Gln or Ala; X_2 is Trp or Leu; X_3 is Gln, Lys, Orn, Ala, or Nle; X_4 is Arg, Lys, or Ala; X_5 is Asn, Orn, Ala, or Nle; X_6 is Met or Leu; and X_7 is Arg or Lys; and

said peptide is selected from the group consisting of SEQ ID NOS: 2-5, 8, 31-37, 47, 49, 51, 63, 65, 67, 70, 72-74, 80-83, and 87-97.

47-48. (Canceled).

49. (Previously Presented) The method of claim 46, wherein said wound is related to posttraumatic tissue injury.

50. (Previously Presented) The method of claim 49, wherein said posttraumatic tissue injury is caused by surgery.

51. (Previously Presented) The method of claim 46, wherein said would is related to thermic injury.

52. (Previously Presented) The method of claim 46, wherein said wound is a result of a metabolic process due to reduced nutritional supply.

53. (Previously Presented) The method of claim 52, wherein said wound is a diabetic ulcer, a leg ulcer, a decubitus ulcer or a gastric ulcer.

54. (Previously Presented) The method of claim 46, wherein said wound is a result of exposure to a toxic compound.

55. (Previously Presented) The method of claim 46, wherein said pharmaceutical composition is locally administered.

56. (Previously Presented) The method of claim 46, wherein said pharmaceutical composition is systemically administered.

57. (New) The method of claim 46, wherein:

said peptide is derived from amino acid 20 to amino acid 31 of human lactoferrin, and

said peptide is selected from the group consisting of SEQ ID NOS: 70, 72-74, 80-83, and 87-97.